<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7144320\results\search\disease\results.xml">
  <result pre="Rapid Communication: Short Communication Antitumor properties of certain spirooxindoles towards" exact="hepatocellular carcinoma" post="endowed with antioxidant activity S. T. Al-Rashood et al."/>
  <result pre="spirooxindoles 6a-p was examined for their anticancer effect towards HepG2" exact="hepatocellular carcinoma" post="and PC-3 prostate cancer cell lines. Spirooxindole 6a was"/>
  <result pre="for their anticancer effect towards HepG2 hepatocellular carcinoma and PC-3" exact="prostate cancer" post="cell lines. Spirooxindole 6a was found to be an"/>
  <result pre="their anticancer effect towards HepG2 hepatocellular carcinoma and PC-3 prostate" exact="cancer" post="cell lines. Spirooxindole 6a was found to be an"/>
  <result pre="a variety of chemical structures are needed for prevention of" exact="cancer" post="and to augment chemotherapies for different malignancies. Being abundant"/>
  <result pre="derivatives 6aâ€&quot;p as efficient anti-proliferative agents towards the aggressive triple-negative" exact="breast cancer" post="MDA-MB-231 cell line25. In the current study, the reported"/>
  <result pre="6aâ€&quot;p as efficient anti-proliferative agents towards the aggressive triple-negative breast" exact="cancer" post="MDA-MB-231 cell line25. In the current study, the reported"/>
  <result pre="addition, 6aâ€&quot;p were examined for their anticancer effect towards HepG2" exact="hepatocellular carcinoma" post="and PC-3 prostate cancer cell lines. Furthermore, spirooxindole 6a"/>
  <result pre="for their anticancer effect towards HepG2 hepatocellular carcinoma and PC-3" exact="prostate cancer" post="cell lines. Furthermore, spirooxindole 6a was then assessed for"/>
  <result pre="their anticancer effect towards HepG2 hepatocellular carcinoma and PC-3 prostate" exact="cancer" post="cell lines. Furthermore, spirooxindole 6a was then assessed for"/>
  <result pre="was then assessed for its apoptosis induction potential in HepG2" exact="hepatocellular carcinoma" post="cell line, so as to obtain some mechanistic insights"/>
  <result pre="Spirooxindoles 6aâ€&quot;p were evaluated for their anti-proliferative potency towards HepG2" exact="liver cancer" post="and PC-3 prostate cancer cell lines. Both cells lines"/>
  <result pre="6aâ€&quot;p were evaluated for their anti-proliferative potency towards HepG2 liver" exact="cancer" post="and PC-3 prostate cancer cell lines. Both cells lines"/>
  <result pre="for their anti-proliferative potency towards HepG2 liver cancer and PC-3" exact="prostate cancer" post="cell lines. Both cells lines were cultured as monolayers"/>
  <result pre="their anti-proliferative potency towards HepG2 liver cancer and PC-3 prostate" exact="cancer" post="cell lines. Both cells lines were cultured as monolayers"/>
  <result pre="anti-HCC activity against HepG2 cell line, and for their anti-prostate" exact="cancer" post="activity against PC-3 cell line by the use of"/>
  <result pre="control. The anti-proliferative activities of tested spirooxindoles against the two" exact="cancer" post="cell lines were measured as IC50 (in Î¼M) value"/>
  <result pre="1. Table 1. Anti-proliferative activities of spirooxindoles 6aâ€&quot;p against HepG2" exact="hepatocellular carcinoma" post="and PC-3 prostate cancer cell lines. Compound R Ar"/>
  <result pre="activities of spirooxindoles 6aâ€&quot;p against HepG2 hepatocellular carcinoma and PC-3" exact="prostate cancer" post="cell lines. Compound R Ar IC50 (ÂµM) HepG2 PC-3"/>
  <result pre="of spirooxindoles 6aâ€&quot;p against HepG2 hepatocellular carcinoma and PC-3 prostate" exact="cancer" post="cell lines. Compound R Ar IC50 (ÂµM) HepG2 PC-3"/>
  <result pre="spirooxindoles were more effective towards HCC HepG2 cells rather than" exact="prostate cancer" post="PC-3 cells, except compounds 6f, 6â€‰m and 6n which"/>
  <result pre="were more effective towards HCC HepG2 cells rather than prostate" exact="cancer" post="PC-3 cells, except compounds 6f, 6â€‰m and 6n which"/>
  <result pre="prepared spirooxindoles possessed moderate to modest growth inhibitory activity towards" exact="prostate cancer" post="PC-3 cells with IC50 in the range of 11.8â€‰âˆ’â€‰43.7â€‰ÂµM."/>
  <result pre="spirooxindoles possessed moderate to modest growth inhibitory activity towards prostate" exact="cancer" post="PC-3 cells with IC50 in the range of 11.8â€‰âˆ’â€‰43.7â€‰ÂµM."/>
  <result pre="with dual activity against both here examined HepG2 and PC-3" exact="cancer" post="cell lines, were tested for their potential cytotoxic impact"/>
  <result pre="phase may imply apoptosis as a potential mechanism for 6a-induced" exact="cancer" post="cell death. Figure 3. Effect of spirooxindole 6a on"/>
  <result pre="mechanism carried out by this transporter that utilised by many" exact="cancer" post="cell lines as a drug-resistance mechanism38,39. Figure 5(B) represents"/>
  <result pre="derivatives (6aâ€&quot;p) was examined for its anticancer effect towards HepG2" exact="hepatocellular carcinoma" post="and PC-3 prostate cancer cell lines. Spirooxindoles 6aâ€&quot;p were"/>
  <result pre="for its anticancer effect towards HepG2 hepatocellular carcinoma and PC-3" exact="prostate cancer" post="cell lines. Spirooxindoles 6aâ€&quot;p were more effective towards HCC"/>
  <result pre="its anticancer effect towards HepG2 hepatocellular carcinoma and PC-3 prostate" exact="cancer" post="cell lines. Spirooxindoles 6aâ€&quot;p were more effective towards HCC"/>
  <result pre="6aâ€&quot;p were more effective towards HCC HepG2 cells rather than" exact="prostate cancer" post="PC-3 cells, except compounds 6f, 6â€‰m and 6n. In"/>
  <result pre="were more effective towards HCC HepG2 cells rather than prostate" exact="cancer" post="PC-3 cells, except compounds 6f, 6â€‰m and 6n. In"/>
  <result pre="Inhib Med Chem2019;34:260â€&quot;70. 4HassanSZ, GheitaTA, KenawySA, et al.Oxidative stress in" exact="systemic lupus erythematosus" post="and rheumatoid arthritis patients: relationship to disease manifestations and"/>
  <result pre="Med Chem2019;34:260â€&quot;70. 4HassanSZ, GheitaTA, KenawySA, et al.Oxidative stress in systemic" exact="lupus erythematosus" post="and rheumatoid arthritis patients: relationship to disease manifestations and"/>
  <result pre="GheitaTA, KenawySA, et al.Oxidative stress in systemic lupus erythematosus and" exact="rheumatoid arthritis" post="patients: relationship to disease manifestations and activity. Int J"/>
  <result pre="KenawySA, et al.Oxidative stress in systemic lupus erythematosus and rheumatoid" exact="arthritis" post="patients: relationship to disease manifestations and activity. Int J"/>
  <result pre="synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative" exact="breast cancer" post="MDAMB-231 cells. J Enzym Inhib Med Chem2018;33:309â€&quot;18. 26DenizotF, LangR.Rapid"/>
  <result pre="of novel spirooxindoles with potential cytotoxic activity against triple-negative breast" exact="cancer" post="MDAMB-231 cells. J Enzym Inhib Med Chem2018;33:309â€&quot;18. 26DenizotF, LangR.Rapid"/>
 </snippets>
</snippetsTree>
